A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| BMS-779788 | BMS-779788 is a LXR partial agonist with IC50 values of 68 nM and 14 nM for LXRα and LXRβ respectively. BMS-779788 induces LXR target genes in blood in vivo with EC50 value of 610 nM, and significantly increases plasma triglyceride and LDL cholesterol. Synonyms: BMS-779788; BMS 779788; BMS779788; BMS-788; BMS 788; BMS788; XL-652; XL652; XL652; EXEL 04286652; EXEL04286652; EXEL-04286652;; 2-[2-[2-(2-chlorophenyl)propan-2-yl]-1-[4-(3-methylsulfonylphenyl)phenyl]imidazol-4-yl]propan-2-ol. CAS No. 918348-67-1. Molecular formula: C28H29ClN2O3S. Mole weight: 509.061. |  |
| BMS-791325 HCl | BMS-791325 HCl is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50 < 28 nM). In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. BMS-791325 was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation. BMS-791325 is currently under Phase III trials. Synonyms: Beclabuvir hydrochloride; BMS-791325 HCl; BMS 791325 HCl; BMS791325 HCl. Grades:> 98%. CAS No. 958002-36-3. Molecular formula: C36H46ClN5O5S. Mole weight: 696.304. | |
| BMS-794833 | BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM. Synonyms: BMS794833; BMS 794833. Grades: 0.98. CAS No. 1174046-72-0. Molecular formula: C23H15ClF2N4O3. Mole weight: 468.845. | |
| BMS-794833 | BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC50s of 15 and 1.7 nM, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1174046-72-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10497. |  |
| BMS 795311 | BMS 795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor (IC50 = 4 nM in an enzyme-based scintillation proximity assay) that inhibits cholesteryl ester transfer and increases HDL-C levels in vivo. Synonyms: BMS 795311; BMS795311; BMS-795311; N-[(1R)-1-[3-(Cyclopropyloxy)-4-fluorophenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide. Grades: ≥98% by HPLC. CAS No. 939390-99-5. Molecular formula: C33H23F10NO3. Mole weight: 671.52. | |
| BMS-813160 | BMS-813160 is an effective and selective CCR2/CCR5 antagonist with potential immunomodulatory and anti-tumor activities. It inhibits the activation of CCR2/CCR5 mediated signal transduction pathways, and may inhibit the inflammatory process, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. Synonyms: BMS813160; BMS 813160; BMS 813160-Bio-X. CAS No. 1286279-29-5. Molecular formula: C25H40N8O2. Mole weight: 484.6. | |
| BMS-813160 | BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC 50 s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1286279-29-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-109593. | |
| BMS-833923 | BMS-833923 is an orally bioavailable small-molecule Smo (Smoothened) inhibitor with potential antineoplastic activity. It inhibits the sonic hedgehog (shh) pathway protein Smo, which may result in suppression of shh signaling pathway. Synonyms: BMS 833923; XL139; N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide. Grades: >98%. CAS No. 1059734-66-5. Molecular formula: C30H27N5O. Mole weight: 473.57. | |
| BMS-833923 | BMS-833923 (XL-139) is an orally biocompatible Smoothened (Smo) inhibitor with anti-tumor activity. It can inhibit the binding of BODIPY cyclopamine to SMO in a dose-dependent manner with an IC50 of 21 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: XL-139. CAS No. 1059734-66-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13809. | |
| BMS-856 | BMS-856 shows low nanomolar inhibition of 17beta-HSD3 enzymatic activity. It displays inhibition of 17beta-HSD3-mediated cellular conversion of AdT to testosterone and inhibits the 17beta-HSD3-mediated conversion of testosterone necessary to promote AR-dependent transcription. BMS-856 can be used for endocrine therapy of prostate cancer. Uses: Endocrine therapy of prostate cancer. Synonyms: BMS 856; BMS856; UNII-7IQ5DK4G01; 7IQ5DK4G01; 2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-Benzamide. Grades: 98%. CAS No. 863382-83-6. Molecular formula: C29H25ClN2O5. Mole weight: 516.97. | |
| BMS-863233 HCl | BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BMS-863233; BMS863233; BMS 863233; XL-413; XL413; XL 413. CAS No. 1169562-71-3. Molecular formula: C14H13Cl2N3O2. Mole weight: 289.72. | |
| BMS-870145 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| BMS-890068 | BMS-890068 is an acyclic P1 bi-cyclopropane acylsulfonamidetripeptide that can be used as hepatitis C virus (HCV) NS3 protease inhibitor. Uses: The treatment of hepatitis c. Synonyms: BMS-890068; BMS 890068; BMS890068. | |
| BMS 903452 | G-protein-coupled receptor 119 agonists can stimulate glucose-dependent insulin release by direct action in the pancreas and promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. BMS-903452 is a selective G-protein-coupled receptor 119 (GRP119) agonist and it is efficacious in both acute and chronic in vivo rodent models of diabetes. Till now, no development was reported for the treatment of Type 2 diabetes mellitus using BMS-903452. Uses: Type 2 diabetes mellitus. Synonyms: BMS-903452; BMS 903452; BMS903452; 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one. Grades: 98%. CAS No. 1339944-47-6. Molecular formula: C21H19Cl2FN4O4S. Mole weight: 513.37. | |
| BMS-905 | BMS-905 is a Dual Antagonist of Toll-like Receptors 7 and 8 (TLR7/8). Uses: Designed for use in research and industrial production. Additional or Alternative Names: BMS-905; BMS 905; BMS905. Product Category: Antagonists. Appearance: Solid powder. CAS No. 2205846-49-5. Molecular formula: C23H29N3. Mole weight: 347.51. Purity: >98%. IUPACName: 2-(2,6-Dimethylpyridin-4-yl)-5-piperidin-4-yl-3-propan-2-yl-1H-indole. Canonical SMILES: CC(C1=C(C2=CC(C)=NC(C)=C2)NC3=C1C=C(C4CCNCC4)C=C3)C. Product ID: ACM2205846495. Alfa Chemistry ISO 9001:2015 Certified. Categories: BMS-906024. |  |
| BMS-906024 | BMS-906024, a selective and orally active γ-secretase inhibitor, is a potent inhibitor of pan-Notch receptors with IC50s of 1.6, 0.7, 3.4 and 2.9 nM for Notch-1, -2, -3 and -4 receptors, respectively. It has broad-spectrum antineoplastic activity. Synonyms: (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; NSC-780812; Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-. Grades: ≥98%. CAS No. 1401066-79-2. Molecular formula: C26H26F6N4O3. Mole weight: 556.50. | |
| BMS-906024 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-906024 | BMS-906024 is an orally active and selective ?-secretase (gamma secretase) inhibitor. BMS-906024 is a potent pan-Notch receptors inhibitor with IC50s of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, -2, -3, and -4 receptors, respectively. BMS-906024 demonstrates broad-spectrum antineoplastic activity[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1401066-79-2. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-15670. | |
| BMS-908662 | BMS-908662 is a Raf kinase inhibitor with potential antineoplastic activity. It can specifically inhibit RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. Phase I for the treatment of Colorectal cancer and Malignant melanoma was discontinued. Uses: Colorectal cancer; malignant melanoma. Synonyms: methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindolin-1-yl)-1H-benzo[d]imidazol-2-yl)carbamate;BMS908662; BMS-908662; BMS 908662; XL281; XL 281; XL-281. Grades: 98%. CAS No. 870603-16-0. Molecular formula: C24H19ClN4O4. Mole weight: 462.89. | |
| BMS 911543 | BMS 911543. Group: Biochemicals. Alternative Names: N,N-Dicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dihydro-1-methyl-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide. Grades: Highly Purified. CAS No. 1271022-90-2. Pack Sizes: 5mg. Molecular Formula: C23H28N8O, Molecular Weight: 432.52. US Biological Life Sciences. |  Worldwide |
| BMS-911543 | BMS-911543 is an orally available JAK inhibitor with selectivity for JAK2. It inhibts JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. Synonyms: BMS 911543. Grades: >98%. CAS No. 1271022-90-2. Molecular formula: C23H28N8O. Mole weight: 432.532. | |
| BMS-911543 | BMS-911543 is a selective JAK2 inhibitor, with IC 50 s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 ( IC 50 , 75, 360, 66 nM, respectively). Uses: Scientific research. Group: Signaling pathways. CAS No. 1271022-90-2. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15270. | |
| BMS-919373 | This active molecular is a Kv1.5 potassium channel inhibitor originated by Bristol-Myers Squibb. Treatment for paroxysmal atrial fibrillation is in Phase II clinical trials. Treatment for Acute coronary syndromes and Atrial fibrillation is in Phase I clinical trials. Synonyms: BMS 919373; BMS919373; 3-Pyridinesulfonamide, 5-[5-phenyl-4-[(2-pyridinylmethyl)amino]-2-quinazolinyl]-; 5-[5-Phenyl-4-[(2-pyridinylmethyl)amino]-2-quinazolinyl]-3-pyridinesulfonamide; 5-[5-phenyl-4-[[(pyridin-2-yl)methyl]amino]quinazolin-2-yl]pyridine-3-sulfonamide. Grades: 98%. CAS No. 1272353-82-8. Molecular formula: C25H20N6O2S. Mole weight: 468.54. | |
| BMS-935177 | BMS-935177 is a potent and selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 3 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. BMS-935177 inhibited calcium flux in human Ramos B cells with IC50 of 27 nM and inhibited CD69 surface expression in peripheral B cells stimulated with anti-IgM and anti-IgG. Synonyms: BMS-935177; BMS935177. Grades: ≥98%. CAS No. 1231889-53-4. Molecular formula: C31H26N4O3. Mole weight: 502.56. | |
| BMS-936559 | Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. Synonyms: MDX1105; BMS936559; MDX 1105; BMS 936559; MDX-1105; BMS-936559; Anti PD L1; PD-L1 inhibitor -Bristol-Myers Squibb. | |
| BMS-955176 | BMS-955176 is the second generation HIV-1 maturation inhibitor. Synonyms: BMS-955176 free base|BMS-955176|UNII-4CA9IAU7RJ|4CA9IAU7RJ|GSK3532795|139 2312-45-6|1392312-45-6 (free base) |GSK-3532795|CHEMBL3827379|SCHEMBL1269786 2|BMS-955176 TFA|EX-A3677|BDBM50450015|BMS955176|DB15193 |2097784-79-5|AC-36687|HY-112714|CS-0062829|4 ( (1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR) 3a- ( (2- (1, 1-Dioxidothiomorpholino) ethyl ) amino )-5a, 5b, 8, 8, 11a-penta methyl -1- (prop-1-en-2-yl ) -2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13boctad eca hydro1Hcyclopenta [a] chrysen-9-yl ) benzoic Acid|4-((1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR)-3a-((2-(1, 1-dioxido-4-thiomorpholinyl)ethyl)amino)-1-isopropenyl-5a, 5b, 8, 8, 11a-pentamethyl-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid|4-((1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR)-3a-((2-(1, 1-dioxidothiomorpholino)ethyl)amino)-5a, 5b, 8, 8, 11a-pentamethyl-1-(prop-1-en-2-yl)-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid|4-[(1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR)-3a-[[2-(1, 1-dioxido-4-thiomorpholinyl)ethyl]amino]-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13b-octadecahydro-5a, 5b, 8, 8, 11a-pentamethyl-1-(1-methylethenyl)-1H-cyclopenta[a]chrysen-9-yl]-benzoic acid|4-[(1R, 3aS, 5aR, 5bR. .. Grades: ≥98% (HPLC). CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691. | |
| BMS-955176 free base | GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. GSK3532795 combines broad coverage of polymorphic viruses (EC50 <15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK3532795; GSK-3532795; GSK 3532795; BMS-955176; BMS 955176; BMS955176. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691.03. Purity:>98%. IUPACName: 4 - ((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR) - 3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13boctadecahydro - 1H - cyclopenta[a]chrysen-9-yl)benzoic Acid. Canonical SMILES: O=C(O)C1=CC=C(C2=CC[C@@]3(C)[C@@](C2(C)C)([H])CC[C@@]4(C)[C@]5(C)CC[C@](CC[C@H]6C(C)=C)(NCCN(CC7)CCS7(=O)=O)[C@@]6([H])[C@@]5([H])CC[C@]34[H])C=C1. Product ID: ACM1392312456. Alfa Chemistry ISO 9001:2015 Certified. | |
| BMS-955176 TFA | BMS-955176 TFA is the second generation HIV-1 maturation inhibitor. Synonyms: MS-955176 TFA. CAS No. 2097784-79-5. Molecular formula: C44H63F3N2O6S. Mole weight: 805.05. | |
| BMS-955829 | BMS-955829 shows excellent Metabotropic glutamate receptor 5 (mGluR5) binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype. BMS-955829 is a potent mGluR5 Positive allosteric modulator (PAM) (EC50 = 2.6 ± 1.0 nM; n=6), devoid of inherent mGluR5 agonist activity (EC50 > 30μM). It may become a new drug candidate for the treatment of schizophrenia. Uses: Schizophrenia. Synonyms: BMS-955829; BMS 955829; BMS955829. (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. Grades: 98%. CAS No. 1375751-08-8. Molecular formula: C22H14F2N2O2. Mole weight: 376.36. | |
| BMS 961 | BMS 961. Group: Biochemicals. Grades: Purified. CAS No. 185629-22-5. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS 961 | BMS 961 is a potent and selective retinoic acid receptor gamma (RARγ) agonist with an IC50 value of 30 nM. Synonyms: BMS961; BMS-961; 3-Fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino]-benzoic acid; Benzoic acid, 3-fluoro-4-[[2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]-. Grades: ≥97% by HPLC. CAS No. 185629-22-5. Molecular formula: C23H26FNO4. Mole weight: 399.45. | |
| BMS-978587 | BMS-978587 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 ( IDO-1 ) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: IDO-IN-4. CAS No. 1629125-65-0. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18769. | |
| BMS-983970 | BMS-983970 is an oral pan-Notch inhibitor for the treatment of cancer. Synonyms: BMS-983970; BMS 983970; BMS983970. Grades: >98%. CAS No. 1584713-87-0. Molecular formula: C26H26F4N4O3. Mole weight: 518.5. | |
| BMS-986016 | | |
| BMS 986020 | BMS 986020 is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells. It inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS 986020 is used for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: BMS-986020; BMS986020. Grades: ≥98%. CAS No. 1257213-50-5. Molecular formula: C29H26N2O5. Mole weight: 482.5. | |
| BMS-986020 | BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist[1]. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 ?M, 6.2 ?M, and 7.5 ?M for BSEP, MRP4, and MDR3, respectively[2]. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF)[3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AM152. CAS No. 1257213-50-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100619. | |
| BMS-986020 sodium | BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist[1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 ?M, 6.2 ?M, and 7.5 ?M for BSEP, MRP4, and MDR3, respectively[2]. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF)[3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AM152 sodium. CAS No. 1380650-53-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-100619A. | |
| BMS-986094 | BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC 50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INX-08189. CAS No. 1234490-83-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13337. | |
| BMS-986120 | BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 ( PAR4 ) antagonist, with IC 50 s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1478712-37-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19837. | |
| BMS-986120 | BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vascular occlusion. It was just completed a Phase I trail in in Thrombosis. Synonyms: BMS-986120; BMS 986120; BMS986120; 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine. Grades: 98%. CAS No. 1478712-37-6. Molecular formula: C23H23N5O5S2. Mole weight: 513.59. | |
| BMS 986122 | BMS 986122 is a positive allosteric modulator of the μ-Opioid receptor. It significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells. BMS 986122 potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant μ-opioid receptors with EC50 of 8.9 μM. It also enhances [35S]GTPγ binding stimulated by the μ-opioid agonist DAMGO by 7- and 4.5-fold in C6μ glioma cell membranes. Synonyms: BMS-986122; BMS986122; 2-(3-bromo-4-methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine. Grades: ≥98%. CAS No. 313669-88-4. Molecular formula: C16H15BrClNO3S2. Mole weight: 448.8. | |
| BMS-986122 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-986124 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-986141 | BMS-986141 is a potential medication under the clinical trial that evaluates the pharmacokinetics of BMS-986141 in participants with hepatic impairment compared to healthy participants. Synonyms: Unii-W530irz40G. CAS No. 1478711-48-6. Molecular formula: C27H23N5O5S2. Mole weight: 561.6. | |
| BMS-986142 | Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase. It is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling. BMS-986142 is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM. It potently inhibits BCR-stimulated expression of CD69 on B cells in human whole blood with IC50 of 90 nM. Synonyms: BMS-986142; BMS986142. Grades: ≥98%. CAS No. 1643368-58-4. Molecular formula: C32H30F2N4O4. Mole weight: 572.60. | |
| BMS-986158 | BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins with potential antineoplastic activity. Synonyms: 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol; BMS-986158; BMS 986158; BMS986158. CAS No. 1800340-40-2. Molecular formula: C30H33N5O2. Mole weight: 495.62. | |
| BMS-986158 | BMS-986158 is a potent BET inhibitor with IC 50 s of 6.6 and 5?nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1800340-40-2. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg. Product ID: HY-101567. | |
| BMS-986165 | BMS-986165 is a potent and selective TYK2 inhibitor that blocks signal transduction of IL-23, IL-12, and type I IFNs. It binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM), and is highly selective against a panel of 265 kinases and pseudokinases. BMS-986165 is under a phase III clinical trial for the treatment of Psoriasis. Synonyms: Tyk2-IN-4; BMS 986165; BMS986165. Grades: 98%. CAS No. 1609392-27-9. Molecular formula: C20H19D3N8O3. Mole weight: 425.47. | |
| BMS-986176 | BMS-986176, also known as LX9211, is a highly selective, CNS penetrant, potent AAK1 inhibitor from a novel class of bi(hetero)aryl ethers. BMS-986176/LX9211 (34) showed excellent efficacy in two rodent neuropathic pain models and excellent central nervous system (CNS) penetration and target engagement at the spinal cord with an average brain to plasma ratio of 20 in rat. The compound exhibited favorable physicochemical and pharmacokinetic properties, had an acceptable preclinical toxicity profile, and was chosen for clinical trials. Uses: Designed for use in research and industrial production. Additional or Alternative Names: LX9211; LX-9211; LX 9211; BMS-986176; BMS 986176; BMS986176. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1815613-42-3. Molecular formula: C19H23F4N3O. Mole weight: 385.41. Purity: >98%. IUPACName: ( S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin. Canonical SMILES: CC(C)C[C@@](N)(C)COC1=C(C(F)F)N=C(C2=CC(C(F)F)=NC=C2)C=C1. Product ID: ACM1815613423. Alfa Chemistry ISO 9001:2015 Certified. | |
| BMS 986187 | BMS 986187 is a potent and selective δ-opioid receptor positive allosteric modulator (EC50 = 30 nM) exhibiting 100-fold selectivity for δ over μ-opioid receptor. Synonyms: BMS 986187; BMS986187; BMS-986187; 3,4,5,6,7,9-Hexahydro-3,3,6,6-tetramethyl-9-[4-[(2-methylphenyl)methoxy]phenyl]-1H-xanthene-1,8(2H)-dione. Grades: ≥98% by HPLC. CAS No. 684238-37-7. Molecular formula: C31H34O4. Mole weight: 470.61. | |
| BMS-986187 | BMS-986187 is an δ-opioid receptor -selective positive allosteric modulator (PAM) with an EC 50 of 0.03 μM and a pK B of 6.02 (~1 μM). BMS-986187 has no observable PAM activity at the μ-receptor (EC 50 =3 μM) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 684238-37-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120613. | |
| BMS 986188 | BMS 986188 is a novel potent and selective positive allosteric modulator of the delta-opioid receptor. It is selective for δ- over μ-opioid receptors with EC50 of 10 μM in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1, respectively. Synonyms: MS-986188; BMS 986188. Grades: ≥98%. CAS No. 1776115-10-6. Molecular formula: C30H31BrO4. Mole weight: 535.5. | |
| BMS-986189 | BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987[1][2]. Uses: Scientific research. Group: Peptides. CAS No. 1629665-96-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P10375. | |
| BMS-986195 | BMS-986195 is a Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 0.1 nM. Synonyms: Branebrutinib; BMS 986195; BMS986195. Grades: ≥98% by HPLC. CAS No. 1912445-55-6. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS986195 R-isomer | An R isomer of BMS-986195, a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Synonyms: (R)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; (R)-Branebrutinib; (R)-BMS-986195. CAS No. 1912445-70-5. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS-986205 | BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. It is undergoing a phase I/II clinical trial for the bladder and cervical cancer therapy in combination with nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Uses: Drug combination with nivolumab. Synonyms: BMS-986205; BMS 986205; BMS986205; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide. CAS No. 1923833-60-6. Molecular formula: C24H24ClFN2O. Mole weight: 410.917. | |
| BMS-986224 | BMS-986224 is a potent, selective and orally active APJ receptor agonist (Kd = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr1) apelin-13. BMS-986224 has the potential for the research of heart failure[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2055200-88-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139485. | |
| BMS-986235 | BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LAR-1219. CAS No. 2253947-47-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-131180. | |
| BMS-986278 | BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K b s of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2170126-74-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139853. | |
| BMS-986299 | BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC 50 of 1.28 μM. (patent WO2018152396A1). Uses: Scientific research. Group: Signaling pathways. CAS No. 2242952-69-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139396. | |
| BMS-986365 | BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor ( AR ) PROTAC degrader, capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor ( AR ), as well as various AR mutants. BMS-986365 shows significant in vivo potency, degrading AR , inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. (Blue: HY-W247437; Black: linker (HY-W126831); Pink: HY-168697) [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CC-94676. CAS No. 2446928-30-7. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-158101. | |
| BMS-986397 | BMS-986397. Uses: Scientific research. Group: Signaling pathways. CAS No. 2564486-44-6. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-159646. | |
| BMS CCR2 22 | BMS CCR2 22 is a potent CCR2 antagonist. Synonyms: N-[2-[[2-[ (4-methylsulfanylbenzoyl) amino]cyclohexyl]amino]-2-oxoethyl]-2- (propan-2-ylcarbamoylamino) -5- (trifluoromethyl) benzamide. CAS No. 445479-97-0. Molecular formula: C28H34F3N5O4S. Mole weight: 593.66. | |
| BMS CCR2 22 | BMS CCR2 22. Group: Biochemicals. Grades: Purified. CAS No. 445479-97-0. Pack Sizes: 1mg, 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS-P5 | BMS-P5 is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 blocks multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1549811-36-0. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-137655. | |
| BMSpep-57 | BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs[1]. Uses: Scientific research. Group: Peptides. CAS No. 1629655-80-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P3143. | |
| BMT-1438 | BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and other autoimmune diseases. It has a preference for JAK1 and JAK3. BMT-1438 showed excellent effect both in vitro and in a collagen-induced arthritis mouse model. Uses: The potential treatment of rheumatoid arthritis and other autoimmune diseases. Synonyms: BMT-1438; BMT 1438; BMT1438. | |
| BMT-145027 | BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy. Synonyms: BMT-145027; BMT 145027; BMT145027; 3-[4-chloro-3-(trifluoromethyl)phenyl]-4-cyclopropyl-6-phenyl-2H-pyrazolo[3,4-b]pyridine-5-carbonitrile. CAS No. 2018282-44-3. Molecular formula: C23H14ClF3N4. Mole weight: 438.83. | |
| Bmt I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (Hind III-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 20-fold overdigestion with enzyme about 95% of the dna fragments can be ligated and recut. Group: Restriction Enzymes. Purity: 1000U; 5000U. GCTAG↑C C↓GATCG. Activity: 20000u.a./ml. Appearance: 10 X SE-buffer W. Storage: -20°C. Form: Liquid. Source: An E.coli strain that carries the cloned Bmt I gene from Bacillus megaterium S2. Pack: 10 mM Tris-HCl (pH 7.5); 200 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 200 μg/ml BSA; 50% glycerol. Cat No: ET-1036RE. |  |
| Bmu I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (HindIII-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 2-fold overdigestion with enzyme about 75% of the dna fragments can be ligated and 95% may be recut. Group: Restriction Enzymes. Purity: 50U; 250U. ACTGGG(N)5↑ TGACCC(N)4&darr. Activity: 500-1000u.a./ml. Appearance: 10 X SE-buffer Y. Storage: -20°C. Form: Liquid. Source: Bacillus megaterium S87. Pack: 10 mM Tris-HCl (pH 7.5); 250 mM NaCl; 0.1 mM EDTA; 7 mM 2-mercaptoethanol; 50% glycerol. Cat No: ET-1037RE. | |
Our database is helping our users find suppliers everyday.
